Jeito Capital

Jeito Capital is a Paris-based independent investment firm deploying significant global capital to accelerate the clinical development of life-saving therapeutics. The firm focuses on pharma and biotech with a particular emphasis on programs addressing high unmet medical need, where dedicated capital can advance clinical milestones and unlock value through development progress, partnerships, or transactions. AI is not a stated focus, though computational drug discovery and biomarker work that fits within therapeutic programs are consistent with the mandate.

Jeito invests across Series A, Series B, Series C, and Growth rounds with checks of $25M and above, signaling its position as a lead or significant syndicate participant in capital-intensive therapeutic financings. The geographic reach is global, anchored by the Paris headquarters with active engagement across European and US biotech ecosystems. Companies should generally have a clear clinical asset or a near-term clinical inflection point, a credible regulatory pathway, and a development plan capable of absorbing larger institutional capital across multiple milestones. The check size aligns with leading or co-leading specialized rounds rather than small follow-on participation.

Named partners and detailed portfolio company information are not specified in the materials reviewed, so this profile reflects limited public information regarding the team and named investments. Founders considering Jeito should prepare a clinical and regulatory strategy that extends multiple years, a view on competitive positioning within their therapeutic area, and a clear thesis for value-creation events such as pivotal readouts, partnerships, or strategic transactions. The most productive first conversation focuses on the science, the unmet need, and the planned use of substantial capital across defined development milestones.